The two companies will collaborate to develop and commercialise KLH-2109 for the treatment of Endometriosis
KLH-2109 is an oral gonadotropin-releasing hormone (GnRH) antagonist that has undergone three Phase 2a studies in endometriosis in Japan.
Ernest Loumaye, CEO and co-founder of ObsEva, said: "Endometriosis is a painful, chronic disease and a leading cause of infertility, affecting more than 170 million women worldwide.
"ObsEva is advancing a pipeline of clinical stage, novel compounds focused on supporting pregnancy, including indications that impact fertility as well as the overall well-being of women.”
Under the terms of the agreement ObsEva will acquire the exclusive rights to develop and commercialise KLH-2109 worldwide, excluding Asia.
Both companies will collaborate in parallel on the development of KLH-2109, represented in ObsEva's pipeline as OBE2109.
The financial terms of the deal are not being disclosed.
Loumaye said: “This collaboration recognises the additive nature of our expertise together with that of Kissei and we look forward to advancing together with them this potentially best-in-class treatment option for women worldwide."